Allergan Aesthetics, an AbbVie Company, has announced the acquisition of Luminera Dermal Fillers. The line includes Hydryalix and Hydryal hyaluronic acid (HA)-based fillers, Crystalys, a calcium hydroxyapatite (CaHA) filler, and HArmonyCa, which is comprised of a combination of cross-linked HA with embedded CaHA microspheres and is indicated for facial soft tissue augmentation. HArmonyCa is currently commercially available only in Israel and Brazil.
“The addition of the Luminera assets adds innovative technology, complementing our leading JUVEDERM filler franchise. We welcome the Luminera team as we continue to build our global aesthetics company and a world-class product offering for healthcare professionals and patients around the world,” said Carrie Strom, SVP, AbbVie, and president, Global Allergan Aesthetics.
Allergan Aesthetics acquired Luminera's full dermal filler portfolio as well as its R&D pipeline.
Luminera Chairman Dadi Segal, PhD, added, “We believe bringing together key, innovative Luminera assets with the support of Allergan Aesthetics will provide an even brighter future for our people, products and a more expanded offering for our customers. This is a tremendous opportunity to further build, develop and collaborate with a leading global aesthetics company.”
